Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Accumulated Expenses (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Accumulated Expenses for 15 consecutive years, with $538875.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 21.01% year-over-year to $538875.0, compared with a TTM value of $538875.0 through Sep 2025, down 21.01%, and an annual FY2024 reading of $704000.0, down 1.08% over the prior year.
  • Accumulated Expenses was $538875.0 for Q3 2025 at BioRestorative Therapies, up from $359250.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.2 million in Q1 2021 and bottomed at $58351.0 in Q3 2021.
  • Average Accumulated Expenses over 5 years is $409400.1, with a median of $359250.0 recorded in 2025.
  • The sharpest move saw Accumulated Expenses soared 1875.36% in 2021, then plummeted 87.28% in 2022.
  • Year by year, Accumulated Expenses stood at $134970.0 in 2021, then fell by 3.63% to $130072.0 in 2022, then surged by 447.15% to $711686.0 in 2023, then fell by 1.08% to $704000.0 in 2024, then dropped by 23.46% to $538875.0 in 2025.
  • Business Quant data shows Accumulated Expenses for BRTX at $538875.0 in Q3 2025, $359250.0 in Q2 2025, and $179625.0 in Q1 2025.